Identifying the most promising oncology candidates early remains one of the biggest challenges in drug development. By integrating MOL2CLIN into Microsoft Discovery, researchers can simulate efficacy, safety, and clinical outcomes before costly experimental and clinical stages, enabling smarter, data-driven decisions. … Read More
In drug development, access to diverse and representative patient data is often a limiting factor, especially when studying rare subgroups. This is where synthetic data can offer powerful, practical value. At InSilicoTrials, we use synthetic data not as a replacement
Synthetic Data’ – Are We All Talking About the Same Thing? In the rapidly evolving world of healthcare and drug development, data is the driving force behind innovation. Yet, the lack of cross-institute shared access frameworks and the need to
The Paradigm Shift in Preclinical Testing The FDA has announced a strategic shift away from animal testing, citing that over 90% of drugs successful in animals fail FDA approval due to human safety and efficacy issues—especially in cancer, Alzheimer’s, and
The HSBC Healthcare Annual Report for the first half of 2024 provides an extensive analysis of the healthcare sector, focusing on trends in venture capital investments, biopharma, medical devices, and health tech. This report, authored by HSBC Innovation Banking, serves
In recent years, the US Congress and the US Food and Drug Administration (FDA) have emphasized the importance of including underrepresented populations in clinical trials. This push for diversity is not just a regulatory requirement but a critical step towards
InSilicoTrials recently participated in the DIA 2024 Global Annual Meeting, (16-20 June, San Diego), sharing valuable insights on the use of in silico trials, digital twins, and AI-powered predictive intelligence in drug development and patient care. This event provided a
InSilicoTrials recently collaborated with a team of experts led by Tina M. Morrison on a significant initiative supported by the FDA and the U.S. Department of Health and Human Services. The project, titled “A Strategic Imperative for Accelerating Breakthroughs and
The BRAINTEASER Community of Practice Second webinar Advances in digital technology are helping us to predict the onset of a disease, how it will progress, or which is the best treatment option for a particular person. In other words, technology
InSilicoTrials partners with Axoltis Pharma to leverage advanced modeling technology, generating predictive analyses of disease progression in virtual subjects based on the baseline characteristics of actual enrolled patients. This collaboration will enhance the development of Axoltis’s NX210c by accelerating the
InSilicoTrials collaborates with Telomir Pharmaceuticals, applying cutting-edge AI and simulation technologies to optimize the development of Telomir-1, a promising agent in the battle against age-related conditions, by improving its safety profile and reducing development costs. BALTIMORE, March 07, 2024 (GLOBE
The realm of healthcare and life sciences is undergoing a transformative shift, fueled by the advent and integration of data-driven technologies. At the forefront of this revolution is the burgeoning use of synthetic data, a groundbreaking development poised to redefine